American Journal of Obstetrics & Gynecology
Volume 200, Issue 4 , Pages 392.e1-392.e10 , April 2009

Circulating angiogenic factors in gestational proteinuria without hypertension

  • Alexander M. Holston, MD

      Affiliations

    • Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD
    • Division of Epidemiology, Statistics, and Prevention Research, Department of Health and Human Services, National Institute of Child Health and Human Development, Bethesda, MD
    • ,
  • Cong Qian, MS

      Affiliations

    • Allied Technology Group, Rockville, MD
    • ,
  • Kai F. Yu, PhD

      Affiliations

    • Division of Epidemiology, Statistics, and Prevention Research, Department of Health and Human Services, National Institute of Child Health and Human Development, Bethesda, MD
    • ,
  • Franklin H. Epstein, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA
    • ,
  • S. Ananth Karumanchi, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA
    • Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA
    • ,
  • Richard J. Levine, MD

      Affiliations

    • Division of Epidemiology, Statistics, and Prevention Research, Department of Health and Human Services, National Institute of Child Health and Human Development, Bethesda, MD
    • Corresponding Author InformationReprints: Richard J. Levine, MD, Divison of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, Department of Health and Human Services, Bethesda, MD 20892

Received 27 June 2008 ,Revised 22 August 2008 ,Accepted 7 October 2008.

References 

  1. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592–1594
  2. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–649
  3. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005
  4. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17:3–18
  5. Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003;88:2348–2351
  6. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683
  7. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658
  8. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003;101:1266–1274
  9. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707–716
  10. Mattot V, Moons L, Lupu F, et al. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol. 2002;13:1548–1560
  11. Liu A, Dardik A, Ballermann BJ. Neutralizing TGF-beta1 antibody infusion in neonatal rat delays in vivo glomerular capillary formation 1. Kidney Int. 1999;56:1334–1348
  12. Kitamoto Y, Takeya M, Tokunaga H, Tomita K. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku J Exp Med. 2001;195:43–54
  13. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605–12608
  14. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I, potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434–1447
  15. Li Z, Zhang Y, Ying Ma J, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension. 2007;50:686–692
  16. Miyamoto K, Kitamoto Y, Tokunaga H, et al. Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat. Lab Invest. 2004;84:1126–1136
  17. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest. 1999;104:913–923
  18. Shimizu A, Masuda Y, Mori T, et al. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol. 2004;15:2655–2665
  19. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  20. Stettler RW, Cunningham FG. Natural history of chronic proteinuria complicating pregnancy. Am J Obstet Gynecol. 1992;167:1219–1224
  21. Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69–76
  22. Levine RJ, Esterlitz JR, Raymond EG, et al. Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Control Clin Trials. 1996;17:442–469
  23. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565
  24. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006;194:1034–1041
  25. Sibai BM, Gordon T, Thom E, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study: the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine units. Am J Obstet Gynecol. 1995;172:642–648
  26. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease?. BJOG. 2004;111:298–302
  27. Yoshimatsu J, Matsumoto H, Goto K, Shimano M, Narahara H, Miyakawa I. Relationship between urinary albumin and serum soluble fms-like tyrosine kinase 1 (sFlt-1) in normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 2006;128:204–208
  28. Strevens H, Wide-Swensson D, Hansen A, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG. 2003;110:831–836
  29. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006;194:551–556
  30. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188:177–182
  31. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9–23
  32. Ramin SM, Vidaeff AC, Yeomans ER, Gilstrap LC. Chronic renal disease in pregnancy. Obstet Gynecol. 2006;108:1531–1539

 This study was supported by funds and salary from the intramural research program of the National Institutes of Health and by salary from the US Navy; by the National Institute of Child Health and Human Development under contracts N01-HD-1-3121 through 3126, N01-HD-3154, and N01-HD-5-3246, with cofunding from the National Heart, Lung, and Blood Institute (Calcium for Preeclampsia Prevention trial database and specimen repository); and by National Institutes of Health Grants DK065997 and HL079594 (S.A.K., an investigator of the Howard Hughes Medical Institute).

 The views expressed are those of the authors and do not reflect the official policy or position of the Department of Defense or the US Government.

 Dr Karumanchi reports having served as a consultant to Abbott, Beckman Coulter, Roche, and Johnson & Johnson and having been named co-inventor on multiple provisional patents that were filed by Beth Israel Deaconess Medical Center for the use of angiogenesis-related proteins for the diagnosis and treatment of preeclampsia. These patents have been nonexclusively licensed to several companies.

 Cite this article as: Holston AM, Qian C, Yu KF, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol 2009;200:392.e1-392.e10.

PII: S0002-9378(08)02045-0

doi: 10.1016/j.ajog.2008.10.033

American Journal of Obstetrics & Gynecology
Volume 200, Issue 4 , Pages 392.e1-392.e10 , April 2009

Article Tools

* Image Usage & Resolution